---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-001591"
form_type: "8-K"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:27:55.399412+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alpha Healthcare Acquisition Corp. III merges with Carmell Therapeutics at $150M implied equity value

## Summary
- Carmell shareholders receive 15M ALPA Class A shares; implied Carmell equity value $150M.
- Combined company expected market cap ~$328M; Carmell shareholders own ~46% post-close.
- Transaction expected to close H1 2023; combined co. to list on Nasdaq as 'CTCX'.
- Carmell is a Phase 2 biotech with allogeneic plasma-based biomaterials; FDA Fast Track for tibia fracture.
- Rajiv Shukla to become Chairman, Randy Hubbell to serve as CEO of combined company.

## SEC filing metadata
- accession: 0001193125-23-001591
- form_type: 8-K
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/0001193125-23-001591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/d411625d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-001591
- JSON: https://secwatch.observer/filing/0001193125-23-001591.json
- Plain text: https://secwatch.observer/filing/0001193125-23-001591.txt

## Key facts
- Material Agreements
  Longevity Health Holdings, Inc. entered into Business Combination Agreement with Carmell Therapeutics Corporation valued at an implied Carmell equity value of $150,000,000 (effective 2023-01-04).
  - Action: entry
  - Agreement: merger
  - Counterparty: Carmell Therapeutics Corporation
  - Value: an implied Carmell equity value of $150,000,000
  - Effective: 2023-01-04
  source text: On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (the " Company "), entered into a business combination agreement (the " Business Combination Agreement ") by and among the Company, Candy Merger Sub, Inc., a Delaware corporation (" Merger Sub "), and Carmell Therapeutics Corporation, a Delaware corporation (" Carmell ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/0001193125-23-001591-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.